“We believe there is a need in the marketplace for a midsized CRO with the specialization and research capabilities of a big CRO, but without the cost structure and typical headaches that can accompany working with a big CRO,” David Fox, Executive Vice President, Client Services, told Outsourcing-Pharma.com.
“Being a specialty CRO with phase I sites enables us to provide services to our sponsors from very early in the clinical development process right up until drug and/or device approval,” explained Fox, adding that as a midsize CRO it is also able to place a “greater focus on PM and CRA retention.”
The company’s expanded services include clinical research sites and full-service study management for early-stage clinical research and specialized therapies and medicines development.
“Together, WCCT and Medelis are continuing our vision of becoming the global leader in the development of specialized medicines and therapies,” said Fox.